Who owns Neuralink? Ownership structure explained (2026)

Neuralink is the most closely watched company in brain-computer interfaces, the field building implants that let a person control a computer with thought alone. It designs a coin-sized device, the N1, that a surgical robot stitches into the brain with hair-thin electrode threads. Since its first human implant in January 2024, it has become the public face of a technology that was science fiction a decade ago.

The company also sits inside Elon Musk's cluster of private ventures, alongside SpaceX and xAI. That connection shapes everything about how Neuralink is owned, funded, and governed. Musk supplied much of the early capital, controls the company, and gives it a level of public attention that no other brain-implant startup enjoys.

Understanding who owns Neuralink matters because the stakes are unusually high. This is a medical device implanted in human brains, funded by venture investors who expect a return, and led by one of the most polarizing figures in technology. Who controls the company, who funds it, and how much oversight sits above it all bear directly on how the technology develops.

Neuralink Corp. was founded in 2016 by Elon Musk and a founding team of eight: Max Hodak, Benjamin Rapoport, Dongjin "DJ" Seo, Paul Merolla, Philip Sabes, Tim Gardner, Tim Hanson, and Vanessa Tolosa. The company was incorporated in the United States and first based in San Francisco, later consolidating operations in Fremont, California. It has since built a large campus near Austin, Texas, close to Tesla's Gigafactory.

The core product is an implantable brain-computer interface. Neuralink's N1 implant reads neural activity through more than 1,000 electrodes on flexible threads, which a purpose-built surgical robot inserts into the brain. The stated near-term goal is to restore autonomy to people with paralysis, letting them control a cursor, a keyboard, or an assistive robotic arm directly. Musk has described far longer-term ambitions, including treating blindness and eventually linking the human brain to artificial intelligence.

Neuralink does not disclose meaningful revenue. It is a pre-commercial company whose product is still in clinical trials, so its value rests on future potential rather than current sales. Its most recent private valuation was about $9 billion, a figure of the sort a business valuation calculator can only approximate in the absence of public financials. By 2026 the company reported implanting its device in more than a dozen human trial participants across the United States, the United Kingdom, and Canada.

Neuralink has no public stock. Its shares do not trade on any exchange, and the company has not announced an IPO. It has funded itself entirely through private capital: Musk's own money in the early years, followed by venture capital rounds. There is no parent company. Neuralink is an independent private business, though it shares an investor base, a founder, and management ties with Musk's other ventures.

Elon Musk is Neuralink's largest shareholder and controlling owner. He co-founded the company, seeded it with a reported $100 million or more of his own capital in the early phase, and has retained a dominant equity position ever since. Reporting on his exact stake varies. Some accounts place it above 50 percent, while others estimate it in the 40 to 50 percent range. Neuralink has not published a precise figure.

What is clear is that Musk controls the company. He sets its direction, is its public voice, and holds a founder's position reinforced by a large equity stake. This mirrors how he operates his other private companies, including SpaceX and xAI, where he holds controlling ownership rather than a passive investment. The other founders supplied much of the scientific and engineering work, but Musk supplied the financial bedrock and secured a controlling share.

Neuralink stayed quiet on outside fundraising in its early years, relying on Musk and a small group of backers. It began raising larger institutional rounds in 2021. Reported figures vary across private-market trackers, and the company has not published a full breakdown.

Note: Trackers estimate Neuralink has raised roughly $1.85 billion in total since 2016, including Musk's early contributions and a smaller round before 2021. The company has not confirmed a complete cumulative figure.

Founders Fund, the venture firm co-founded by Peter Thiel, is Neuralink's most prominent institutional backer. It led the 2023 Series D and returned for the 2025 Series E. Founders Fund has a long record of backing Musk-linked and deep-technology companies, including the defense manufacturer Anduril, and its repeated participation signals continued confidence in Neuralink's long-term thesis.

Vy Capital, a Dubai-based firm, led the 2021 Series C and has invested across Musk's ventures. ARK Invest, the firm run by Cathie Wood, and Sequoia Capital co-led the 2025 Series E, bringing a high-profile growth investor and one of Silicon Valley's best-known venture firms onto the cap table. Google Ventures (GV), Alphabet's venture arm, joined in the Series C.

Later rounds also drew Thrive Capital, Lightspeed Venture Partners, DFJ Growth, Valor Equity Partners, Human Capital, Qatar Investment Authority, and the UAE-backed G42. Individual backers in earlier rounds included Sam Altman, the CEO of OpenAI, and Ken Howery, a co-founder of PayPal and Founders Fund.

Neuralink has given no indication that a public listing is near. As a pre-revenue medical-device company still running clinical trials, it is years away from the kind of financial track record public markets expect. Musk has historically kept his companies private for as long as possible, giving him tighter control and freedom from quarterly reporting. Neuralink's ownership is likely to stay concentrated in Musk and its venture investors for the foreseeable future.

Jared Birchall serves as Neuralink's chief executive officer. He is best known as the head of Musk's family office and has managed Musk's personal wealth since 2016. Birchall holds administrative or executive roles across several Musk ventures, including the Boring Company and xAI. His role at Neuralink reflects how closely the company is tied to Musk's broader operation, with a trusted lieutenant handling corporate affairs while Musk sets the vision.

Dongjin "DJ" Seo is a co-founder and serves as president and chief operating officer. He is one of only two founders still at the company, alongside Musk, and leads much of the day-to-day engineering and operations. Seo joined at founding as a young neural-engineering researcher and rose into the top operational role as other founders departed.

Elon Musk is the founder, controlling shareholder, and driving force. Although Birchall carries the CEO title, Musk is the decision-maker on strategy and the company's public representative. His control of the equity and his willingness to fund the company give him final say over its direction.

Neuralink has not published a detailed board roster. As a private, Musk-controlled company, governance sits primarily with Musk and his close associates, with major investors such as Founders Fund typically holding stakes that come with board or observer rights. The specifics have not been disclosed, so board composition is inferred rather than confirmed.

Neuralink's path through the U.S. Food and Drug Administration has been contested. The FDA reportedly rejected an early application over safety concerns before granting approval in May 2023 for human trials under an investigational device exemption. The company implanted its first patient, Noland Arbaugh, in January 2024. Within weeks, a majority of the implant's electrode threads retracted from his brain tissue, degrading performance before engineers recovered function through software changes. The episode underscored how experimental the technology remains and drew fresh attention to the FDA's oversight of it.

Neuralink has faced sustained scrutiny over its animal research. The U.S. Department of Agriculture opened an inquiry into potential animal-welfare violations, and the advocacy group Physicians Committee for Responsible Medicine alleged that experiments on monkeys caused severe suffering, including partial paralysis and brain swelling. Critics have also noted that the company's internal animal-testing oversight panel was largely staffed by its own employees, raising questions about independence. Neuralink has defended its animal-care practices, and a 2023 USDA review reported no violations beyond a self-reported 2019 incident.

Neuralink has drawn interest from multiple federal bodies. The U.S. Department of Transportation investigated the company's handling and transport of implants that had been in contact with animals, over hazardous-materials concerns. Separately, reporting indicated that the Securities and Exchange Commission examined issues connected to the company. These probes sit alongside the animal-welfare questions and add regulatory uncertainty for a company whose product must clear a high safety bar.

Musk's central role has generated conflict-of-interest concerns, sharpened by his 2025 government work. Members of Congress questioned whether his position leading the Department of Government Efficiency, which affected staffing at agencies including the FDA, created conflicts given that the same agency regulates Neuralink. A U.S. Senate subcommittee sent letters seeking information on the issue. Because Musk controls Neuralink and simultaneously held influence over parts of the federal government, critics argued the arrangement risked giving the company an unfair advantage over competitors. Neuralink has not been found to have acted improperly, but the questions illustrate how Musk's ownership carries political as well as commercial weight.

Neuralink's ownership structure concentrates control in one person to a degree that is rare even among private startups. Because Musk holds a controlling stake and funded much of the company himself, he can pursue an ambitious, long-horizon research agenda without answering to public shareholders focused on quarterly results. That freedom has let Neuralink move quickly, but it also means the company's direction depends heavily on a single owner's priorities and risk tolerance.

The venture backing brings both validation and pressure. Investors including Founders Fund, ARK Invest, Sequoia Capital, and Vy Capital have committed hundreds of millions of dollars and expect an eventual return. That is a significant bet on a pre-revenue company, well outside the risk profile of most startup fundraising. Their capital funds the trials and manufacturing the company needs, and their continued participation across rounds has kept Neuralink's valuation climbing even as the science remains unproven.

Concentrated ownership also raises accountability questions that matter more here than in most industries. Neuralink implants devices in human brains, so the incentives of its owners and the strength of its oversight are not abstract concerns. When the controlling owner is also a highly visible political figure, the line between the company's interests and outside influence becomes harder to police, which is why the conflict-of-interest questions have followed Neuralink so closely.

For patients, researchers, and the broader field, ownership shapes how the technology advances and who benefits. A Musk-controlled private company can invest patiently and take risks a public company might avoid, but it also concentrates enormous decision-making power over a sensitive medical technology in the hands of one owner and a small circle of investors.

Jared Birchall is the CEO of Neuralink. He also runs Elon Musk's family office and holds roles across several of Musk's companies. Musk, the founder and controlling shareholder, sets the company's strategic direction, while co-founder DJ Seo serves as president and COO.

No. Neuralink is a privately held company with no public stock listing, and it has not announced an IPO. Its shares are held by Musk, its founders and employees, and its venture investors. There is no way for public investors to buy Neuralink stock directly.

Neuralink was founded in 2016 by Elon Musk and a team of eight scientists and engineers, including Max Hodak, Benjamin Rapoport, DJ Seo, Paul Merolla, Philip Sabes, Tim Gardner, Tim Hanson, and Vanessa Tolosa. Only Musk and Seo remain at the company today.

Elon Musk is the largest shareholder and controlling owner, with a stake reported at or above 50 percent, though estimates vary and Neuralink has not disclosed an exact figure. Major institutional investors include Founders Fund, ARK Invest, Sequoia Capital, Vy Capital, Google Ventures, Thrive Capital, and Lightspeed Venture Partners.

Neuralink has raised roughly $1.85 billion since 2016, according to private-market trackers, across rounds including a ~$205 million Series C in 2021, a ~$280 million Series D in 2023, and a ~$650 million Series E in 2025. Its most recent valuation was about $9 billion, up from a reported $5 billion in 2023.

Musk does not own Neuralink outright, but he is its founder, largest shareholder, and controlling owner. He funded much of the company's early work and holds a stake reported at or above 50 percent. Venture investors and the company's founders and employees hold the remaining equity.